Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $6.85M |
| Net Income (Most Recent Fiscal Year) | $-235.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1467.24% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -40.22% |
| Return on Assets (Trailing 12 Months) | -29.95% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.28 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.89 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 133.55M |
| Free Float | 124.09M |
| Market Capitalization | $1.75B |
| Average Volume (Last 20 Days) | 0.69M |
| Beta (Past 60 Months) | 1.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.09% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |